Author Archives: admin


The bioreactors market was valued at US$ 2,958.50 million in 2019 and is projected to reach US$ 5,169.01 million by 2027; it is expected to grow at a…

New York, June 05, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Bioreactors Market Forecast to 2027 - COVID-19 Impact and Global Analysis by Cell ; Molecule ; Technology ; End User, and Geography" - https://www.reportlinker.com/p05908638/?utm_source=GNW

A bioreactor is equipment or system engineered to provide biologically active environment for the production of various medical and pharmaceutical compounds.The vessel is used to carry out a chemical process, which involves organisms or biochemically active substances derived from such organisms.

This process can either be aerobic or anaerobic.The bioreactors are commonly cylindrical, ranging in size from liters to cubic meters, and are generally made of stainless steel.

Bioreactors provide a controllable environment, in terms of pH, temperature, nutrient supply, and shear stress for any cells.The use of single-use bioreactors has increased in the modern biopharmaceutical processes in the last few years.This can be attributed to their unique ability to allow enhanced process flexibility, reduce investment requirements, and limit operational costs.

Also, many companies have developed single-use bioreactors for the production of a wide range of therapeutics. For instance, Distek Inc., has developed a benchtop single-use bioreactor system for recombinant protein production. Single-use bioreactors reduce the risks of contamination and decrease production turnaround times. Moreover, the reduction in validation time has been one of the prime benefits of single-use bioreactors. The rising adoption of single-use bioreactors for upstream bioprocessing is driving the growth of the market. For instance, Sartorius AG offers a wide range of single-use bioreactors. The company provides ambr 15 for a 10-15 mL microbioreactor scale and Biostat STR for 50-2000 L.The global bioreactors market is segmented on the basis of cell, molecule, technology, and end user.The bioreactors market, by molecule, is segmented into monoclonal antibodies, vaccines, recombinant proteins, stem cells, gene therapy, and others.

The monoclonal antibodies segment held the largest share of the market in 2019.However, the stem cell segment is projected to register the highest CAGR in the market during the forecast period.

Based on cell, the bioreactors market is segmented into mammalian cells, bacterial cells, yeast cells, and others.Based on technology, the market is segmented into wave-induced motion sub, stirred sub, single-use bubble column, and others.

Based on end user, the market is segmented into research and development organizations, biopharma manufacturers, contract manufacturing organizations (CMOs).A few of the essential primary and secondary sources referred to while preparing the report are the Food and Drug Administration (FDA), World Health Organization (WHO), Organization for Economic Co-operation and Development, National Institutes of Health (NIH), and Centers for Disease Control and Prevention (CDC), among others.Bioreactors Market Forecast to 2027 - Covid-19 Impact and Global Analysis by Cell, Molecule, Technology, End User, and GeographyThe bioreactors market was valued at US$ 2,958.50 million in 2019 and is projected to reach US$ 5,169.01 million by 2027; it is expected to grow at a CAGR of 7.3% from 2020 to 2027. A bioreactor is equipment or system engineered to provide biologically active environment for the production of various medical and pharmaceutical compounds.The vessel is used to carry out a chemical process, which involves organisms or biochemically active substances derived from such organisms.

This process can either be aerobic or anaerobic.The bioreactors are commonly cylindrical, ranging in size from liters to cubic meters, and are generally made of stainless steel.

Bioreactors provide a controllable environment, in terms of pH, temperature, nutrient supply, and shear stress for any cells.The use of single-use bioreactors has increased in the modern biopharmaceutical processes in the last few years.This can be attributed to their unique ability to allow enhanced process flexibility, reduce investment requirements, and limit operational costs.

Also, many companies have developed single-use bioreactors for the production of a wide range of therapeutics. For instance, Distek Inc., has developed a benchtop single-use bioreactor system for recombinant protein production. Single-use bioreactors reduce the risks of contamination and decrease production turnaround times. Moreover, the reduction in validation time has been one of the prime benefits of single-use bioreactors. The rising adoption of single-use bioreactors for upstream bioprocessing is driving the growth of the market. For instance, Sartorius AG offers a wide range of single-use bioreactors. The company provides ambr 15 for a 10-15 mL microbioreactor scale and Biostat STR for 50-2000 L.The global bioreactors market is segmented on the basis of cell, molecule, technology, and end user.The bioreactors market, by molecule, is segmented into monoclonal antibodies, vaccines, recombinant proteins, stem cells, gene therapy, and others.

The monoclonal antibodies segment held the largest share of the market in 2019.However, the stem cell segment is projected to register the highest CAGR in the market during the forecast period.

Based on cell, the bioreactors market is segmented into mammalian cells, bacterial cells, yeast cells, and others.Based on technology, the market is segmented into wave-induced motion sub, stirred sub, single-use bubble column, and others.

Based on end user, the market is segmented into research and development organizations, biopharma manufacturers, contract manufacturing organizations (CMOs).A few of the essential primary and secondary sources referred to while preparing the report are the Food and Drug Administration (FDA), World Health Organization (WHO), Organization for Economic Co-operation and Development, National Institutes of Health (NIH), and Centers for Disease Control and Prevention (CDC), among others.Read the full report: https://www.reportlinker.com/p05908638/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Original post:
The bioreactors market was valued at US$ 2,958.50 million in 2019 and is projected to reach US$ 5,169.01 million by 2027; it is expected to grow at a...

Stem Cell Therapy Market to Rise Globally During 2020-2027 with Top Key Players and Competitive Analysis – 3rd Watch News

Stem Cell Therapy

Stem Cell Therapy Market provides a birds eye view of the current proceeding within the Stem Cell Therapy market. Further, the report also takes into account the impact of the novel COVID-19 pandemic on the Stem Cell Therapy market and offers a clear assessment of the projected market fluctuations during the forecast period. The different factors that are likely to impact the overall dynamics of the Stem Cell Therapy market over the forecast period (2020-2027) including the current trends, growth opportunities, restraining factors, and more are discussed in detail in the market study.

Leading Players Of Stem Cell Therapy Market:- MEDIPOST, Pharmicell Co., Inc., RichSource, BioTime Inc. (Lineage Cell Therapeutics, Inc.), Mesoblast Limited, Holostem Terapie Avanzate Srl, U.S. Stem Cell, Inc., Caladrius Biosciences, Inc., TiGenix NV, AlloSource

Get Sample PDF Of Stem Cell Therapy Market @https://www.theinsightpartners.com/sample/TIPHE100000991/

Key Reasons to Purchase:

To gain insightful analyses of the Covid-19 Impact on Stem Cell Therapy market and have a comprehensive understanding of the global market and its commercial landscape.

Assess the production processes, major issues, and solutions to mitigate the development risk.

To understand the most affecting driving and restraining forces in the market and its impact on the global Covid-19 Impact on Stem Cell Therapy market.

Learn about the Covid-19 Impact on Stem Cell Therapy market strategies that are being adopted by leading respective organizations.

To understand the future outlook and prospects for the market.

Besides the standard structure reports, we also provide custom research according to specific requirements.

Stem Cell Therapy Market: Regional analysis includes:

An Overview of the Impact of COVID-19 on this Market:

The pandemic of COVID-19 continues to expand and impact over 175 countries and territories. Although the outbreak appears to have slowed in China, COVID-19 has impacted globally. The pandemic could affect three main aspects of the global economy: production, supply chain, and firms and financial markets. National governments have announced largely uncoordinated, country-specific responses to the virus. As authorities encourage social distancing and consumers stay indoors, several businesses are hit. However, coherent, coordinated, and credible policy responses are expected to offer the best chance at limiting the economic fallout.

National governments and international bodies are focused on adopting collaborative efforts to encourage financial institutions to meet the financial needs of customers and members affected by the coronavirus. However, there are some sectors that have remained unscathed from the impact of the pandemic and there are some that are hit the hardest.

Reasons to Purchase Stem Cell Therapy report is:

Gives a complete understanding of the Stem Cell Therapy Market to express competitor information, analysis, and insights to formulate effective RD strategies.

Collect data of the developing participants having the potentially profitable portfolio in this space and create effective counter-strategies to gain competitive benefits.

Note: Access insightful study with over 150+ pages, list of tables & figures, profiling 20+ companies.

Are you a Start-up willing to make it Big in the Business? Grab an Exclusive PDF Brochure@https://www.theinsightpartners.com/buy/TIPHE100000991/

The research study can answer the following Key questions:

About Us:

The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are a specialist in Life Science, Technology, Healthcare, Manufacturing, Automotive and Defense, Food Beverages, Chemical etc.

For More Information Kindly Contact:Call: +1-646-491-9876

Email:[emailprotected]

More:
Stem Cell Therapy Market to Rise Globally During 2020-2027 with Top Key Players and Competitive Analysis - 3rd Watch News

Cellular Reprogramming Tools Market Research Key Players, Industry Overview and forecasts to | 2026 – Weekly Wall

The market research report is a brilliant, complete, and much-needed resource for companies, stakeholders, and investors interested in the global Cellular Reprogramming Tools market. It informs readers about key trends and opportunities in the global Cellular Reprogramming Tools market along with critical market dynamics expected to impact the global market growth. It offers a range of market analysis studies, including production and consumption, sales, industry value chain, competitive landscape, regional growth, and price. On the whole, it comes out as an intelligent resource that companies can use to gain a competitive advantage in the global Cellular Reprogramming Tools market.

Key companies operating in the global Cellular Reprogramming Tools market include , Celgene, BIOTIME, Human Longevity, Advanced Cell Technology, Mesoblast, STEMCELL Technologies, Osiris Therapeutics, Cynata, Astellas Pharma, FUJIFILM Holdings, EVOTEC, Japan Tissue Engineering Cellular Reprogramming Tools

Get PDF Sample Copy of the Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) :

https://www.qyresearch.com/sample-form/form/1803204/global-cellular-reprogramming-tools-market

Segmental Analysis

Both developed and emerging regions are deeply studied by the authors of the report. The regional analysis section of the report offers a comprehensive analysis of the global Cellular Reprogramming Tools market on the basis of region. Each region is exhaustively researched about so that players can use the analysis to tap into unexplored markets and plan powerful strategies to gain a foothold in lucrative markets.

Global Cellular Reprogramming Tools Market Segment By Type:

, Adult Stem Cells, Human Embryonic Stem Cells, Induced Pluripotent Stem Cells, Other

Global Cellular Reprogramming Tools Market Segment By Application:

, Drug Development, Regenerative Medicine, Toxicity Test, Academic Research, Other

Competitive Landscape

Competitor analysis is one of the best sections of the report that compares the progress of leading players based on crucial parameters, including market share, new developments, global reach, local competition, price, and production. From the nature of competition to future changes in the vendor landscape, the report provides in-depth analysis of the competition in the global Cellular Reprogramming Tools market.

Key companies operating in the global Cellular Reprogramming Tools market include , Celgene, BIOTIME, Human Longevity, Advanced Cell Technology, Mesoblast, STEMCELL Technologies, Osiris Therapeutics, Cynata, Astellas Pharma, FUJIFILM Holdings, EVOTEC, Japan Tissue Engineering Cellular Reprogramming Tools

Key questions answered in the report:

For Discount, Customization in the Report: https://www.qyresearch.com/customize-request/form/1803204/global-cellular-reprogramming-tools-market

TOC

1 Report Overview1.1 Study Scope1.2 Key Market Segments1.3 Players Covered: Ranking by Cellular Reprogramming Tools Revenue1.4 Market by Type 1.4.1 Global Cellular Reprogramming Tools Market Size Growth Rate by Type: 2020 VS 2026 1.4.2 Adult Stem Cells 1.4.3 Human Embryonic Stem Cells 1.4.4 Induced Pluripotent Stem Cells 1.4.5 Other1.5 Market by Application 1.5.1 Global Cellular Reprogramming Tools Market Share by Application: 2020 VS 2026 1.5.2 Drug Development 1.5.3 Regenerative Medicine 1.5.4 Toxicity Test 1.5.5 Academic Research 1.5.6 Other 1.6 Study Objectives 1.7 Years Considered 2 Global Growth Trends2.1 Global Cellular Reprogramming Tools Market Perspective (2015-2026)2.2 Global Cellular Reprogramming Tools Growth Trends by Regions 2.2.1 Cellular Reprogramming Tools Market Size by Regions: 2015 VS 2020 VS 2026 2.2.2 Cellular Reprogramming Tools Historic Market Share by Regions (2015-2020) 2.2.3 Cellular Reprogramming Tools Forecasted Market Size by Regions (2021-2026) 2.3 Industry Trends and Growth Strategy 2.3.1 Market Top Trends 2.3.2 Market Drivers 2.3.3 Market Challenges 2.3.4 Porters Five Forces Analysis 2.3.5 Cellular Reprogramming Tools Market Growth Strategy 2.3.6 Primary Interviews with Key Cellular Reprogramming Tools Players (Opinion Leaders) 3 Competition Landscape by Key Players3.1 Global Top Cellular Reprogramming Tools Players by Market Size 3.1.1 Global Top Cellular Reprogramming Tools Players by Revenue (2015-2020) 3.1.2 Global Cellular Reprogramming Tools Revenue Market Share by Players (2015-2020) 3.1.3 Global Cellular Reprogramming Tools Market Share by Company Type (Tier 1, Tier 2 and Tier 3)3.2 Global Cellular Reprogramming Tools Market Concentration Ratio 3.2.1 Global Cellular Reprogramming Tools Market Concentration Ratio (CR5 and HHI) 3.2.2 Global Top 10 and Top 5 Companies by Cellular Reprogramming Tools Revenue in 20193.3 Cellular Reprogramming Tools Key Players Head office and Area Served3.4 Key Players Cellular Reprogramming Tools Product Solution and Service3.5 Date of Enter into Cellular Reprogramming Tools Market3.6 Mergers & Acquisitions, Expansion Plans 4 Market Size by Type (2015-2026)4.1 Global Cellular Reprogramming Tools Historic Market Size by Type (2015-2020)4.2 Global Cellular Reprogramming Tools Forecasted Market Size by Type (2021-2026) 5 Market Size by Application (2015-2026)5.1 Global Cellular Reprogramming Tools Market Size by Application (2015-2020)5.2 Global Cellular Reprogramming Tools Forecasted Market Size by Application (2021-2026) 6 North America6.1 North America Cellular Reprogramming Tools Market Size (2015-2020)6.2 Cellular Reprogramming Tools Key Players in North America (2019-2020)6.3 North America Cellular Reprogramming Tools Market Size by Type (2015-2020)6.4 North America Cellular Reprogramming Tools Market Size by Application (2015-2020) 7 Europe7.1 Europe Cellular Reprogramming Tools Market Size (2015-2020)7.2 Cellular Reprogramming Tools Key Players in Europe (2019-2020)7.3 Europe Cellular Reprogramming Tools Market Size by Type (2015-2020)7.4 Europe Cellular Reprogramming Tools Market Size by Application (2015-2020) 8 China8.1 China Cellular Reprogramming Tools Market Size (2015-2020)8.2 Cellular Reprogramming Tools Key Players in China (2019-2020)8.3 China Cellular Reprogramming Tools Market Size by Type (2015-2020)8.4 China Cellular Reprogramming Tools Market Size by Application (2015-2020) 9 Japan9.1 Japan Cellular Reprogramming Tools Market Size (2015-2020)9.2 Cellular Reprogramming Tools Key Players in Japan (2019-2020)9.3 Japan Cellular Reprogramming Tools Market Size by Type (2015-2020)9.4 Japan Cellular Reprogramming Tools Market Size by Application (2015-2020) 10 Southeast Asia10.1 Southeast Asia Cellular Reprogramming Tools Market Size (2015-2020)10.2 Cellular Reprogramming Tools Key Players in Southeast Asia (2019-2020)10.3 Southeast Asia Cellular Reprogramming Tools Market Size by Type (2015-2020)10.4 Southeast Asia Cellular Reprogramming Tools Market Size by Application (2015-2020) 11 India11.1 India Cellular Reprogramming Tools Market Size (2015-2020)11.2 Cellular Reprogramming Tools Key Players in India (2019-2020)11.3 India Cellular Reprogramming Tools Market Size by Type (2015-2020)11.4 India Cellular Reprogramming Tools Market Size by Application (2015-2020) 12 Central & South America12.1 Central & South America Cellular Reprogramming Tools Market Size (2015-2020)12.2 Cellular Reprogramming Tools Key Players in Central & South America (2019-2020)12.3 Central & South America Cellular Reprogramming Tools Market Size by Type (2015-2020)12.4 Central & South America Cellular Reprogramming Tools Market Size by Application (2015-2020) 13Key Players Profiles13.1 Celgene 13.1.1 Celgene Company Details 13.1.2 Celgene Business Overview 13.1.3 Celgene Cellular Reprogramming Tools Introduction 13.1.4 Celgene Revenue in Cellular Reprogramming Tools Business (2015-2020)) 13.1.5 Celgene Recent Development13.2 BIOTIME 13.2.1 BIOTIME Company Details 13.2.2 BIOTIME Business Overview 13.2.3 BIOTIME Cellular Reprogramming Tools Introduction 13.2.4 BIOTIME Revenue in Cellular Reprogramming Tools Business (2015-2020) 13.2.5 BIOTIME Recent Development13.3 Human Longevity 13.3.1 Human Longevity Company Details 13.3.2 Human Longevity Business Overview 13.3.3 Human Longevity Cellular Reprogramming Tools Introduction 13.3.4 Human Longevity Revenue in Cellular Reprogramming Tools Business (2015-2020) 13.3.5 Human Longevity Recent Development13.4 Advanced Cell Technology 13.4.1 Advanced Cell Technology Company Details 13.4.2 Advanced Cell Technology Business Overview 13.4.3 Advanced Cell Technology Cellular Reprogramming Tools Introduction 13.4.4 Advanced Cell Technology Revenue in Cellular Reprogramming Tools Business (2015-2020) 13.4.5 Advanced Cell Technology Recent Development13.5 Mesoblast 13.5.1 Mesoblast Company Details 13.5.2 Mesoblast Business Overview 13.5.3 Mesoblast Cellular Reprogramming Tools Introduction 13.5.4 Mesoblast Revenue in Cellular Reprogramming Tools Business (2015-2020) 13.5.5 Mesoblast Recent Development13.6 STEMCELL Technologies 13.6.1 STEMCELL Technologies Company Details 13.6.2 STEMCELL Technologies Business Overview 13.6.3 STEMCELL Technologies Cellular Reprogramming Tools Introduction 13.6.4 STEMCELL Technologies Revenue in Cellular Reprogramming Tools Business (2015-2020) 13.6.5 STEMCELL Technologies Recent Development13.7 Osiris Therapeutics 13.7.1 Osiris Therapeutics Company Details 13.7.2 Osiris Therapeutics Business Overview 13.7.3 Osiris Therapeutics Cellular Reprogramming Tools Introduction 13.7.4 Osiris Therapeutics Revenue in Cellular Reprogramming Tools Business (2015-2020) 13.7.5 Osiris Therapeutics Recent Development13.8 Cynata 13.8.1 Cynata Company Details 13.8.2 Cynata Business Overview 13.8.3 Cynata Cellular Reprogramming Tools Introduction 13.8.4 Cynata Revenue in Cellular Reprogramming Tools Business (2015-2020) 13.8.5 Cynata Recent Development13.9 Astellas Pharma 13.9.1 Astellas Pharma Company Details 13.9.2 Astellas Pharma Business Overview 13.9.3 Astellas Pharma Cellular Reprogramming Tools Introduction 13.9.4 Astellas Pharma Revenue in Cellular Reprogramming Tools Business (2015-2020) 13.9.5 Astellas Pharma Recent Development13.10 FUJIFILM Holdings 13.10.1 FUJIFILM Holdings Company Details 13.10.2 FUJIFILM Holdings Business Overview 13.10.3 FUJIFILM Holdings Cellular Reprogramming Tools Introduction 13.10.4 FUJIFILM Holdings Revenue in Cellular Reprogramming Tools Business (2015-2020) 13.10.5 FUJIFILM Holdings Recent Development13.11 EVOTEC 10.11.1 EVOTEC Company Details 10.11.2 EVOTEC Business Overview 10.11.3 EVOTEC Cellular Reprogramming Tools Introduction 10.11.4 EVOTEC Revenue in Cellular Reprogramming Tools Business (2015-2020) 10.11.5 EVOTEC Recent Development13.12 Japan Tissue Engineering 10.12.1 Japan Tissue Engineering Company Details 10.12.2 Japan Tissue Engineering Business Overview 10.12.3 Japan Tissue Engineering Cellular Reprogramming Tools Introduction 10.12.4 Japan Tissue Engineering Revenue in Cellular Reprogramming Tools Business (2015-2020) 10.12.5 Japan Tissue Engineering Recent Development 14Analysts Viewpoints/Conclusions 15Appendix15.1 Research Methodology 15.1.1 Methodology/Research Approach 15.1.2 Data Source15.2 Disclaimer15.3 Author Details

About Us:

QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become the brand of quality assurance in consulting industry.

Continued here:
Cellular Reprogramming Tools Market Research Key Players, Industry Overview and forecasts to | 2026 - Weekly Wall

Cells inside Cells: The Bacteria That Live in Cancer Cells – ETHealthworld.com

In a research conducted by Dr. Ravid Straussman's supported by the Roel C. Buck Career Development Chair and the European Research Council.

Dr. Ravid Straussman stated that cancer cells are comfy havens for bacteria. The conclusion arise from a rigorous study of over 1,000 tumor samples of different human cancers. The study, headed by researchers at the Weizmann Institute of Science, found bacteria living inside the cells of all the cancer types from brain to bone to breast cancer and even identified unique populations of bacteria residing in each type of cancer. The research suggests that understanding the relationship between a cancer cell and its mini-microbiome may help predict the potential effectiveness of certain treatments or may point, in the future, to ways of manipulating those bacteria to enhance the actions of anticancer treatments. The findings of this study were published in Science.

Dr. Ravid Straussman of the Institutes Molecular Cell Biology Department had, several years ago, discovered bacteria lurking within human pancreatic tumor cells; these bacteria were shown to protect cancer cells from chemotherapy drugs by digesting and inactivating these drugs. When other studies also found bacteria in tumor cells, Straussman and his team wondered whether such hosting might be the rule, rather than the exception. To find out, Drs. Deborah Nejman and Ilana Livyatan in Straussmans group and Dr. Garold Fuks of the Physics of Complex Systems Department worked together with a team of oncologists and researchers around the world. The work was also led by Dr. Noam Shental of the Mathematics and Computer Science Department of the Open University of Israel.

Ultimately, the team would produce a detailed study describing, in high resolution, the bacteria living in these cancers brain, bone, breast, lung, ovary, pancreas, colorectal and melanoma. They discovered that every single cancer type, from brain to bone, harbored bacteria and that different cancer types harbor different bacteria species. It was the breast cancers, however, that had the largest number and diversity of bacteria. The team demonstrated that many more bacteria can be found in breast tumors compared to the normal breast tissue surrounding these tumors, and that some bacteria were preferentially found in the tumor tissue rather than in the normal tissue surrounding it.

The team also reported that bacteria can be found not only in cancer cells, but also in immune cells that reside inside tumors. Some of these bacteria could be enhancing the anticancer immune response, while others could be suppressing it a finding that may be especially relevant to understanding the effectiveness of certain immunotherapies, says Straussman. Indeed, when the team compared the bacteria from groups of melanoma samples, they found that different bacteria were enriched in those melanoma tumors that responded to immunotherapy as compared to those that had a poor response.

Straussman thinks that the study can also begin to explain why some bacteria like cancer cells and why each cancer has its own typical microbiome: The differences apparently come down to the choice of amenities offered in each kind of tumor-cell environment. That is, the bacteria may live off certain metabolites that are overproduced by or stored within the specific tumor types. For example, when the team compared the bacteria found in lung tumors from smokers with those from patients who had never smoked, they found variances. These differences stood out more clearly when the researchers compared the genes of these two groups of bacteria: Those from the smokers lung cancer cells had many more genes for metabolizing nicotine, toluene, phenol and other chemicals that are found in cigarette smoke.

In addition to showing that some of the most common cancers shelter unique populations of bacteria within their cells, the researchers believe that the methods they have developed to identify signature microbiomes with each cancer type can now be used to answer some crucial questions about the roles these bacteria play: Are the bacteria freeloaders on the cancer cells surplus metabolites, or do they provide a service to the cell? At what stage do they take up residence? How do they promote or hinder the cancers growth? What are the effects that they have on response to a wide variety of anticancer treatments?

Tumors are complex ecosystems that are known to contain, in addition to cancer cells, immune cells, stromal cells, blood vessels, nerves, and many more components, all part of what we refer to as the tumor microenvironment. Our studies, as well as studies by other labs, clearly demonstrate that bacteria are also an integral part of the tumor microenvironment. We hope that by finding out how exactly they fit into the general tumor ecology, we can figure out novel ways of treating cancer, Straussman says.

See the rest here:
Cells inside Cells: The Bacteria That Live in Cancer Cells - ETHealthworld.com

Bald men at higher risk of having severe coronavirus, shocking new research suggests – Express

Researchers believe the link is so strong that they have called for baldness to be listed as a risk factor called the Gabrin sign This is after Dr Frank Gabrin, the first US physician to die of coronavirus, who was also bald. Lead author of the study, Professor Carlos Wambier of Brown University, told The Telegraph: "We really think that baldness is a perfect predictor of severity."

Recently scientists have hypothesised that coronavirus is more deadlier for men due than women because of testosterone.

Italian doctors have previously found patients given androgen deprivation therapy, which radically cuts testosterone levels, were four times less likely to die from coronavirus.

A protein, TMPRSS2, is driven up by testosterone and scientists think the virus could use this protein to help it unlock cells.

Researchers at Londons Institute for Cancer Research are examining the link further, whilst the University of California, Los Angeles is looking at testosterone-blocking therapy to help with coronavirus treatment.

Testosterone can produce dihydrotestosterone (DHT) which can lead to hair loss.

Though as per South China Morning Post, it is possible to have low levels of testosterone but high levels of DHT.

The further data on baldness further raises the possibility that treatments that cut testosterone could be used to slow the virus down.

Discussions have taken place about a trial using baldness drugs to treat coronavirus.

READ MORE:Chinas Xi Jinping vows to strengthen public health system

A study of 122 patients in three Madrid hospitals found 79 percent of the men were bald.

Howard Soule, executive vice president at the Prostate Cancer Foundation, told Science Magazine: "Everybody is chasing a link between androgens and the outcome of Covid-19.

Karen Stalbow, Head of Policy at Prostate Cancer UK, said: There have been several recent pieces of research which indicate there may be a link between male hormones and increased risk of Covid-19.

This has led some researchers to investigate whether hormone therapies commonly used to treat prostate cancer, such as enzalutamide, could reduce this risk.

DON'T MISS

New Yorks coronavirus came from Europe and NOT China (LATEST)Antimalarial drug study withdrawn as authors deny its authenticity (ANALYSIS)Vaccine summit in UK exceeds target by raising nearly 7 billion(NEWS)

However, most of the research so far has been in the lab, and there is conflicting evidence over whether the hormone therapies have the same impact in the lungs as they would in prostate cells.

There are now several clinical studies starting which hope to address these issues, but much more evidence is needed before we can know whether these hormone therapies would be an effective treatment for Covid-19.

Professor Nick James of the Institute for Cancer Research has warned against using testosterone cutting treatment as a preventive measure due to their severe side effects.

He explained to the Mail on Sunday: Being on these drugs is the male equivalent of going through the menopause.

You would almost certainly cause more harm than good.

According to the NHS, the following people are considered clinically extremely vulnerable: people who have had an organ transplant, people undergoing chemotherapy or antibody treatment for cancer, intense radiotherapy, cancer treatments which affect the immune system, people who have blood or bone marrow cancer, those have had a bone marrow or stem cell transplant in the previous six months, or are still taking immunosuppressant medicine, those with a severe lung condition, those with a condition which puts them at high risk of infection or taking medicines which makes them more likely to do so and expecting mothers with heart conditions.

The list of people are considered at moderate risk includes: Those over 70, expecting mothers, those who have lung conditions which are not severe, those with heart disease, diabetics, those with chronic kidney disease, those with liver disease, those with a condition affecting the brain or nerves and those who are obese.

Previously, environmental factors were hypothesised as being behind the higher risk to men.

This includes the fact men are more likely to be smokers.

Read more from the original source:
Bald men at higher risk of having severe coronavirus, shocking new research suggests - Express

Covid19: Increase in centers moving to collect convalescent plasma is creating a new demand says Chetan Mak.. – ETHealthworld.com

By Smridhi Uppal

In an interaction with EThealthworld, Mr. Chetan Makam, Managing Director, Terumo Penpol Pvt. Ltd talks about how Covid19 has affected the essentials industry in carrying out new normals with respect to terms of supply and demand.

How has the covid-19 pandemic impacted the healthcare sector?The healthcare sector has various segments; delivery of patient care, medical devices, pharma etc. and each of them has been affected in different ways.

TerumoBCT specializes in the manufacturing of medical equipment, particularly equipments used in blood and cell collections. The need for blood never diminishes as patients need blood and blood components for a variety of treatments such as oncology, sickle cell disease, maternal and child health related intervention and for emergency surgeries.

In India, ICMR has initiated a multi-center clinical trial, titled A Phase II, Open Label, Randomized Controlled Trial to Assess the Safety and Efficacy of Convalescent Plasma to Limit COVID-19 Associated Complications in Moderate Disease. (PLACID Trial). About 35 centers across India are approved for the trials and we are supporting several of them.

What are the major investments that TerumoBCT is continuing to make?

We at Terumo Penpol conduct a couple of hundred blood donation drives and promote voluntary blood donation (VBD). Our CSR activities include support for various organizations working in Thalassemia, Hemophilia as well as in stem cell donations.

Terumo is an established company in Kerala. We continue to invest both in the well-being of our associates and in high quality medical devices that support the demands of the local market and in fact, the world. The reliability of the local supply chain, products from our facility make their way around the globe to meet essential healthcare needs.

Terumo Penpol was the first medtech company chosen to participate in the Japan-India Institute of Manufacturing (JIM) program. Overseen by the Japanese Ministry of Economy, Trade and Industry, JIM was borne out of PM Narendra Modis request to his Japanese counterpart Shinzo Abe for support to scale up industrial work skills among Indian youth. Our participation contributes to the Skill India, Make in India and Ayushman Bharat initiatives.

We have invested over the past few years in a comprehensive and established Business Continuity Policy, designed to safeguard associates around the world and ability to deliver products worldwide. Guided by this policy and social responsibility to healthcare, we are committed to providing continuous support to customers so they can continue their business operations during critical events as they rely on the quality of products and the services we provide.

How has your company contributed to combating this pandemic?We continue to operate our factories and provide products and services to our customers globally as they depend on us to collect blood, cells and now plasma, while ensuring that our employees are working in safe conditions.Our parent company, Terumo Corporation, has donated USD 2.4 million in cash and products to support COVID-19 relief efforts worldwide including a USD 1 million donation to the COVID-19 Solidarity Response Fund for WHO. The Solidarity Response Fund supports research and development of new therapies and vaccines, global response to the pandemic, such as tests and personal protective equipment, and education and communication efforts to protect individuals against the infection.

Terumo BCT specifically, focused on unlocking the potential of blood and cells and to the contributing solutions that can have an impact now to fight against COVID-19. In the current context, our products are uniquely placed to cater to various medical interventions. We have a product for convalescent plasma collection, which provides passive immunity to patients with COVID-19 and may help preventing infection in high risk groups, such as healthcare workers. Our Pathogen Reduction Technology system is already being used in many countries to add a layer of safety in blood transfusion and recently for convalescent plasma.

Similarly, we have also a product to help treat respiratory failure in adult patients with confirmed COVID-19. The treatment reduces pro-inflammatory cytokine levels, which cause cytokine storm. The cytokine storm that occurs in some COVID-19 patients, leads to severe inflammation, rapidly progressive shock, respiratory failure, organ failure and death.

What are your expectations from the government?The local government in Thiruvananthapuram, Kerala has provided us with the permissions to operate as an essential industry. Given the treatments and technologies that we can bring to serve more patients, having a process with the regulators to provide emergency use authorization would be a plus. Expedited approvals for products made at multiple locations to ensure business continuity. Relief on import duties on products for the duration of the COVID restrictions to offset the cost of increased freight. Governments can also help by paying outstanding dues immediately.

How do you think this crisis will affect the balance sheets of firms?The key for many companies will be to devise ways to conserve cash as it will allow them to be flexible and respond better to the changing scenarios. its the time to reduce 1 percent from the CSR activities and conserve money for investing tomorrow, by authorizing 2 percent from it.

What are the challenges do you see in Make in India? I am glad to see that the Government of India is bringing in policies to make India a manufacturing hub for medical devices. What is encouraging is that the government is emphasizing on the need for the products to be at par with international standards so that it can cater to the domestic as well as overseas markets. This is indeed a progressive outlook and need to be applauded. One area which needs to be addressed is absence of skilled labour to support domestic/local manufacturing of medical devices.

Hence skilling of labour force is necessary. Another area where there has been a lacuna in most cases is absence of collaborative approach wherein government, private sector and academia join forces for better outcome. However, in the fight against COVID- 19, Indias mitigation response has seen collaborative research and innovation.

Indian Government, academia, and the private sector have come together to bring in pioneering solution. Following this triple helix approach even in the long-term (post-COVID) would benefit the medical device players as well as the customers as it brings together capabilities and resources to solve common problems more efficiently. For the government, it helps address healthcare challenges through innovative and cost-effective approaches.

ICMR has initiated a multi-center clinical trial, titled A Phase II, Open Label, Randomized Controlled Trial to Assess the Safety and Efficacy of Convalescent Plasma to Limit COVID-19 Associated Complications in Moderate Disease. (PLACID Trial). About 35 centers across India are approved for the trials and we are supporting several of them. Hence, it is important to take forward this very important learning from the pandemic and MNCs and local manufacturers should work in tandem to bring in effective solutions to address healthcare challenges in India and globally.

Tell us something about the latest developments and global trends in medical devices associated with blood industry? Spectra Optia apheresis system has seen interesting developments recently. In Covid-19 patients, it aims reduce the number of cytokines and other inflammatory blood proteins that control a cells immune response, filtering the blood and returning it to the patient. The proteins that are removed are typically elevated during infections and can be associated with a cytokine storm that occurs in some COVID-19 patients, leading to severe inflammation, rapidly progressive shock, respiratory failure, organ failure and death.

Another interesting development has been that researchers have established that exposing the novel coronavirus to the vitamin riboflavin and ultraviolet light decreases the viral count in human plasma and whole-blood products, a development that may help lower the possibility of transmission of the virus via blood transfusion. The scientists from Colorado State University (CSU) in the US, has still not been able to decipher if SARS-CoV-2 could be transmitted by blood transfusion. However, it is an interesting development to watch for. The device used is the Mirasol Pathogen Reduction Technology System which has been developed by us.

Visit link:
Covid19: Increase in centers moving to collect convalescent plasma is creating a new demand says Chetan Mak.. - ETHealthworld.com

The latest on the coronavirus outbreak for June 5 – CBC.ca

Unmasking the stealth virus behind COVID-19

Scientists have discovered the pandemic-causing coronavirus is unique in short-circuiting the safest way our immune system kills off a virus which could have implications for using interferon to treat COVID-19, writes CBC's Amina Zafar. Interferon describes a family of proteins produced by the body's immune system in response to an invading viral infection. As the name implies, interferon interferes with the virus's ability to copy itself. Interferon drugs are made in the lab and were used for years to treat hepatitis, a liver infection, as well as other diseases that involve the immune system, such as multiple sclerosis and some cancers.

In May, researchers in Hong Kong published the results of their Phase 2 trial on fewer than 150 people who were admitted to hospital with mild or moderate COVID-19. Participants were randomly assigned to a combination of potential antivirals, including interferon, or placebo injections for two weeks. The findings lent support to the idea of continuing research efforts, including in Canada, to investigate interferon in larger, blinded trials designed to find more definitive answers. Dr. Jordan Feld, a liver specialist at Toronto General Hospital and senior scientist at U of T, previously used interferon to treat people infected with hepatitis. He's now leading a Phase 2 clinical trial to test a targeted form of the drug, called peginterferon lambda, in injections compared with saline placebo injections. "It's kind of like a stealth virus," Feld said of SARS-CoV-2, the virus that causes COVID-19.

Normally, when interferon in the body's white blood cells responds to a viral invader, the interferon sends out a flare signal so nearby cells will work to stop the virus from copying itself or replicating if they, too, should be invaded. In ferrets infected in the lab (a common animal model for studying respiratory viruses), healthy human lung cells and in people with COVID-19, doctors and scientists say it seems like the natural interferon "flies under the radar" of the immune system and isn't activated the way it should be. Feld said the idea behind giving interferon medications is to provide the body with what it should be making to fend off the infection.

The potential therapeutic approach gained scientific backing last month when a study published in the journal Cell showed a "striking" feature of SARS-CoV-2 infection. Ben tenOever is a Canadian-born professor of microbiology at the Icahn School of Medicine at Mount Sinai in New York who led the Cell study and has been flooded with email requests from researchers the world over to test experimental drug compounds against the virus. He said every cell that gets infected has two major jobs:

Most viruses block both of those roles, and what makes SARS-Cov-2 unique is it blocks the call-to-arms function from interferon only. "Treatment with interferon or drugs that induce interferon, the main character in the call to arms, is probably beneficial," tenOever said. "The secret is to do it early," he said, when people have a mild cough and test positive for the virus and haven't developed respiratory distress.

But there could also be mild side-effects. When we're fighting off a flu virus, blame interferon for feeling so crummy, feverish and achy as your immune system kicks into high gear. Likewise, interferon drugs could also lead to flu-like symptoms for a day or two. Individuals enrolling in COVID-19 clinical trials of interferon will need to weigh whether that (potential) shortfall is worth the (potential) payoff of protection from the deadly damage and delivers key answers that only their participation can offer. Matthew Miller, an associate professor of infectious disease and immunology at McMaster University who isn't involved in the clinical trials or studies, called tenOever's paper "an important first step in understanding how our body is responding to this particular new virus."

Click below to watch more from The National

Ontario considering Stage 2 of reopening despite steady stream of new COVID-19 cases

Ontario Premier Doug Ford signalled that he could announce the next phase of loosening Ontario's pandemic restrictions as early as next week, despite a recent uptick in new cases of COVID-19. Stage 2 would allow a wider number of office-based businesses to reopen and expand the maximum size of social gatherings that's currently limited to five. The province's top criteria for further easing its semi-lockdown is a consistent decline over a two- to four-week period in the daily number of new cases.

That benchmark has not declined consistently in the three weeks since May 14, when Ford announced Ontario's first stage of looser restrictions, including allowing non-essential retail stores outside of shopping malls to open for customers. Since that date, Ontario's daily number of reported new cases dipped below 300 only twice; the daily average in that period has been 371, while the average number of new cases daily has trended upward for the past week. By contrast, Quebec's daily number of new cases has steadily declined since early May and has been below 300 for each of the past four days, while British Columbia has not reported more than 30 cases in a single day since May 6. Fifteen of Ontario's 34 public health units have five or fewer active confirmed cases, according to the provincial COVID-19 database on Thursday. None of the public health units north of the Muskoka region has more than three active cases.

Ontario Health Minister Christine Elliott sounded less bullish than the premier about the prospect of a move to loosen restrictions. Elliott said Thursday that the daily count of new cases has "gone back and forth" in the past week to 10 days. "The numbers are gradually going down. We're going to need to see that to continue," she said. There were some positive trends in Ontario's data reported by the provincial Health Ministry including a steady decline in hospitalizations and a decreasing number of long-term care homes with outbreaks but the province's top public health officials have indicated that it's essential they see a steady reduction in the number of new cases daily before recommending a move to Stage 2. A look at the case numbers by their "episode date" (the estimated date of infection, according to the Public Health Ontario interactive data page) shows no sign of a downward trend through the end of May.

Read more about what's happening in Ontario

Federal government to provide $14B to provinces, territories to 'safely' restart economies

The federal government is providing $14 billion to the provinces and territories to help them "safely and carefully" reopen their economies. Prime Minister Justin Trudeau said the money will help pay for more personal protective equipment (PPE) for front-line health-care workers and businesses, and for child care so that parents can go back to work. "Provinces and territories are facing different realities, so flexibility will be important, but here's the bottom line: For seniors and people who need extra support, for kids and workers this plan is here for you," Trudeau said.

Some of the money going to provinces and territories is meant to help them improve the state of long-term care, and to help municipalities continue providing core public services such as transit. The government is saying little at this point about how the money will be carved up and when it will flow. Ontario Premier Doug Ford said it's a "start" but $14 billion falls far short of what's required to address the "massive need" in Canada's most populous province. "The reality is, we have a $23-billion problem in Ontario, and $14 billion for all of Canada ... just won't cut it," he said. Deputy Prime Minister Chrystia Freeland said the government is taking a collaborative approach to fine-tuning the proposal, and stressed that the federal funds are meant to help with the first six to eight months of economic recovery.

Trudeau also announced that Canadians with disabilities will receive a one-time payment of up to $600 to help offset the higher costs of living during the pandemic. The government has announced emergency aid for unemployed Canadians, students, businesses and seniors, but advocates say that people with disabilities were falling through the cracks. Many face increases in the cost of living, such as higher grocery bills and delivery service fees. Conservative MP Dan Albas, his party's critic for employment, workforce development and disability inclusion, said the federal assistance programs announced to date have come with few details and delays in implementation.

Read more about the support for provinces and territories

Canada added 290,000 jobs in May, but unemployment rate inches up to record high

After losing more than three million jobs in March and April, Canada's economy added 290,000 jobs in May, Statistics Canada reported Friday. The data agency reported that 290,000 more people had paid employment in May than in April. The surge means May was the best one-month gain for jobs in Canada in 45 years, although it happened from an admittedly low bar. It also means the economy has now replaced about 10 per cent of the jobs it lost to COVID-19.

The job gains came as a pleasant surprise to economists, most of whom were expecting more job losses for the month. "We are just beginning to dig out of a massively deep hole, and this will take an extended period of time before the rest of the three million job losses can be recouped," Bank of Montreal's Doug Porter said. Despite the gains, Canada's official unemployment rate rose to 13.7 per cent, as 491,000 more people were looking for work in the job market notably students, whose search for summer work isn't normally recorded in the months before May. Porter noted that at 13.7 per cent, Canada's jobless rate is at its highest point since the Second World War. And "that leaves Canada with the dubious distinction of having the highest unemployment rate among all major economies," he said.

The numbers also showed that two-thirds of the new jobs went to men, while women are still bearing the brunt of the impact from COVID-19. That's partly because men are overrepresented in industries like manufacturing and construction, which are recovering faster than other parts of the economy. "As more COVID-19 restrictions are eased in the coming months, labour market outcomes of men and women with children will continue to be monitored," Statistics Canada said. Hassan Yussuff, president of the Canadian Labour Congress, said the data reveals that "women, low-paid workers and racialized workers continue to struggle disproportionately." "Today's numbers also underscore the desperate need for accelerated action on child care to strengthen the job and economic recovery for women," he said.

Read more about Canada's economic situation

Experts say reaching emissions goals and reopening economies amid pandemic shouldn't be mutually exclusive

A recent study published in Nature Climate Change suggests that as a result of global shutdowns because of the COVID-19 pandemic, CO2 emissions in 2020 could drop by roughly seven per cent. The United Nations Environment Program's report from last November found that in order to limit global warming to 1.5 C above pre-industrial levels, CO2 emissions would need to drop by 7.6 per cent annually over the next decade.

At first glance, it might appear as though a devastating economic shutdown is the only way to reach emissions targets set by the UN. But some experts say this isn't the case, and insist there is a way to have economic growth and reduce emissions that adhere to the UN guidelines. "We can't have this [kind of a shutdown] for tackling climate change absolutely not," said Corinne Le Qur, a Canadian professor of climate change science at the University of East Anglia and lead author of the Nature study. "This is a really painful way to get a decrease in emissions." She also noted that it likely won't last, but said this could be an opportunity to funnel money into green technologies as many governments around the world are trying to stimulate their economies during the pandemic.

Don Drummond, an economist who worked for the federal Department of Finance for 23 years, pointed out that emissions in Canada have almost flat-lined, on average, over the past few years during a period of economic growth (prior to the coronavirus pandemic). This, he said, is evidence that reducing emissions to UN guidelines is possible. "We've achieved higher growth with flattening emissions and we can and should go further and achieve positive growth with declining emissions," said Drummond, an adjunct professor at Queen's University and former chief economist at the Toronto-Dominion Bank. Drummond, who was one of the architects of the goods and services tax in 1991, said there is a long history in Canada of scare-mongering that a given new policy will kill the economy, from the GST to the North American Free Trade Agreement. Quite often, it doesn't, he said.

Donation bins begin to reopen in Nova Scotia with easing of COVID-19 restrictions

Donation bins for some organizations in Nova Scotia, including the IWK Foundation and Big Brothers Big Sisters, are reopening as some restrictions around COVID-19 are being lifted in the province https://www.cbc.ca/news/canada/nova-scotia/n-s-reports-no-new-covid-19-cases-1.5600049. "We're doing a very slow return to service," said Shelda Cochrane, a manager with Big Brothers Big Sisters of Greater Halifax. "We just opened up our bins last weekend and we're really just starting to get that message out to the public."

Big Brothers Big Sisters has taken the tape off bins and put up some new signs asking people to take precautions when they place items in the bins. Donated items are sold to Value Village. "We know people have been spring cleaning and holding on to things and they're anxious to get rid of them. But we also want people to be careful when donating," The donations make up about one-third of its annual budget, after expenses, Cochrane said.

The IWK Foundation, seeking used clothing and footwear, reopened its bins this week. The foundation has 600 bins in Nova Scotia and New Brunswick. A third-party organization based in Digby County, N.S., collects items from the bins and resells them. A portion of the proceeds from the bins benefits the IWK Foundation each year, and the donation bin funds will still go toward the cost of programs, new equipment and research at the children's hospital.

Read the full story about the donation bins

Send us your questions

Still looking for more information on the outbreak? Read more about COVID-19's impact on life in Canada, or reach out to us at covid@cbc.ca.

If you have symptoms of the illness caused by the coronavirus, here's what to do in your part of the country.

For full coverage of how your province or territory is responding to COVID-19, visit your local CBC News site.

To get this newsletter daily as an email,subscribe here.

Click below to watch CBC News Network live

More here:
The latest on the coronavirus outbreak for June 5 - CBC.ca

Participation of Somatic Stem Cells, Labeled by a Unique …

A monoclonal antibody (A3) was generated by using rat malignant fibrous histiocytoma (MFH) cells as the antigen. Generally, MFH is considered to be a sarcoma derived from undifferentiated mesenchymal cells. Molecular biological analyses using the lysate of rat MFH cells revealed that A3 is a conformation specific antibody recognizing both N-glycan and peptide. A3-labeled cells in bone marrow were regarded as somatic stem cells, because the cells partly coexpressed CD90 and CD105 (both immature mesenchymal markers). In the hair follicle cycle, particularly the anagen, the immature epithelial cells (suprabasal cells) near the bulge and some immature mesenchymal cells in the disassembling dermal papilla and regenerating connective tissue sheath/hair papilla reacted to A3. In the cutaneous wound-healing process, A3-labeled epithelial cells participated in re-epithelialization in the wound bed, and apparently, the labeled cells were derived from the hair bulge; in addition, A3-labeled immature mesenchymal cells in the connective tissue sheath of hair follicles at the wound edge showed the expansion of the A3 immunolabeling. A3-labeled immature epithelial and mesenchymal cells contributed to morphogenesis in the hair cycle and tissue repair after a cutaneous wound. A3 could become a unique antibody to identify somatic stem cells capable of differentiating both epithelial and mesenchymal cells in rat tissues.

Keywords: N-glycan; antibody; cutaneous wound healing; hair follicle cycle; somatic stem cells.

Continued here:
Participation of Somatic Stem Cells, Labeled by a Unique ...

COVID-19 Impact on Global Cell Therapy Industry 2020: Market Trends, Size, Share, Applications, SWOT Analysis by Top Key Players and Forecast Report…

TheGlobal Cell Therapy Marketwas estimated to be valued at USD XX million in 2018 and is projected to reach USD XX million by 2026, at a CAGR of XX% during 2019 to 2026. Growing aging patient population, the rise in cell therapy transplantations globally, and rising disease awareness drive the growth of the market.

Get Sample Copy of this Report @https://www.orianresearch.com/request-sample/1281174

Cell therapyinvolves the administration of somatic cell preparations for the treatment of diseases or traumatic damages. The objective of this study is to provide long term treatment through a single injection of therapeutic cells.

However, stringent regulatory policies may restrain growth of the market in the forecast period.

The global Cell Therapy Market is primarily segmented based on different type, technique, cell source, technology, end users and region.

On the basis of type, the market is split into:* Allogenic Therapies* Autologous Therapies

On the basis of technique, the market is split into:* Stem Cell Therapy* Cell Vaccine* Adoptive Cell Transfer (ACT)* Fibroblast Cell Therapy* Chondrocyte Cell Therapy* Other Technique

On the basis of cell source, the market is split into:* Bone Marrow* Adipose Tissue* Umbilical Cord Blood-Derived Cells

On the basis of technology, the market is split into:* Viral Vector Technology* Cell Immortalization Technology* Genome Editing Technology

On the basis of end user, the market is split into:* Hospitals & Clinics* Regenerative Medicine Centers* Other End Users

Inquire more or share a question if any before the purchase on this report @https://www.orianresearch.com/enquiry-before-buying/1281174

Moreover, the market is classified based on regions and countries as follows:* North America- U.S., Canada* Europe- U.K., France, Germany, Italy and Rest of Europe* Asia-Pacific- China, Japan, India and Rest of Asia Pacific* South America- Brazil, Mexico and Rest of South America* Middle East & Africa- South Africa, Saudi Arabia and Rest of Middle East & Africa

Key Market Players: The key players profiled in the market include:* Kolon TissueGene, Inc.* JCR Pharmaceuticals Co. Ltd.* Osiris Therapeutics, Inc.* Stemedica Cell Technologies, Inc.* Fibrocell Science, Inc.* Vericel Corporation* Pharmicell Co., Ltd* Anterogen.CO.,LTD.* Baxter Healthcare Corporation.* Arteriocyte Medical Systems

These enterprises are focusing on growth strategies, such as new product launches, expansions, acquisitions, and agreements & partnerships to expand their operations across the globe.

Key Benefits of the Report:* Global, regional, country, type, technique, cell source, technology, end users market size and their forecast from 2018-2026* Identification and detailed analysis on key market dynamics, such as, drivers, restraints, opportunities, and challenges influencing growth of the market* Detailed analysis on industry outlook with market specific PESTLE, and supply chain to better understand the market and build expansion strategies* Identification of key market players and comprehensively analyze their market share and core competencies, detailed financial positions, key product, and unique selling points* Analysis on key players strategic initiatives and competitive developments, such as joint ventures, mergers, and new product launches in the market* Expert interviews and their insights on market shift, current and future outlook, and factors impacting vendors short term and long term strategies* Detailed insights on emerging regions, type, technique, cell source, technology and end users with qualitative and quantitative information and facts

Target Audience:* Cell Therapy Manufactures* Traders, Importers, and Exporters* Raw Material Suppliers and Distributors* Research and Consulting Firms* Government and Research Organizations* Associations and Industry Bodies

Research Methodology:The market is derived through extensive use of secondary, primary, in-house research follows by expert validation and third party perspective, such as, analyst reports of investment banks. The secondary research is the primary base of our study wherein we conducted extensive data mining, referring to verified data products, such as, white papers, government and regulatory published articles, technical journals, trade magazines, and paid data products.

For forecasting, regional demand & supply factors, recent investments, market dynamics including technical growth scenario, consumer behavior, and end use trends and dynamics, and production capacity were taken into consideration. Different weightages have been assigned to these parameters and quantified their market impacts using the weighted average analysis to derive the market growth rate.

The market estimates and forecasts have been verified through exhaustive primary research with the Key Industry Participants (KIPs), which typically include:* Manufacturers* Suppliers* Distributors* Government Body & Associations* Research Institutes

Get Direct Copy of this Report @https://www.orianresearch.com/checkout/1281174

Table of Content1. Introduction2. Research Methodology3. Executive Summary4. Global Cell Therapy Market Overview4.1. Market Segmentation & Scope4.2. Market Trends4.2.1. Drivers4.2.2. Restraints4.2.3. Opportunities4.2.4. Supply Chain Analysis4.3. Global Cell Therapy Market Porters Five Forces Analysis4.4. Global Cell Therapy Market PESTEL Analysis5. Global Cell Therapy Market, by Type5.1. Global Cell Therapy Market, Size and Forecast, 2015-20265.2. Global Cell Therapy Market, by Allogenic Therapies, 2015-20265.2.1. Key driving factors, trends and opportunities5.2.2. Market size and forecast, 2015-20265.3. Global Cell Therapy Market, by Autologous Therapies, 2015-20265.3.1. Key driving factors, trends and opportunities5.3.2. Market size and forecast, 2015-20266. Global Cell Therapy Market, by Technique6.1. Global Cell Therapy Market, Size and Forecast, 2015-20266.2. Global Cell Therapy Market, by Stem Cell Therapy, 2015-20266.2.1. Key driving factors, trends and opportunities6.2.2. Market size and forecast, 2015-20266.3. Global Cell Therapy Market, by Cell Vaccine, 2015-20266.3.1. Key driving factors, trends and opportunities6.3.2. Market size and forecast, 2015-2026

..Continued

Customization Service of the Report:

Orian Research provides customisation of reports as per your need. This report can be personalised to meet your requirements. Get in touch with our sales team, who will guarantee you to get a report that suits your necessities.

About Us:

Orian Research is one of the most comprehensive collections of market intelligence reports on the World Wide Web. Our reports repository boasts of over 500000+ industry and country research reports from over 100 top publishers. We continuously update our repository so as to provide our clients easy access to the worlds most complete and current database of expert insights on global industries, companies, and products. We also specialize in custom research in situations where our syndicate research offerings do not meet the specific requirements of our esteemed clients.

Contact Us:

Ruwin Mendez

Vice President Global Sales & Partner Relations

Orian Research Consultants

US: +1 (832) 380-8827 | UK: +44 0161-818-8027

Email:[emailprotected]

Website: http://www.orianresearch.com/

Read more:
COVID-19 Impact on Global Cell Therapy Industry 2020: Market Trends, Size, Share, Applications, SWOT Analysis by Top Key Players and Forecast Report...

FDA Approves Elixirgen Therapeutics IND Application for Therapy for Telomere Biology Disorders with Bone Marrow Failure – Herald-Mail Media

BALTIMORE, June 4, 2020 /PRNewswire/ -- Elixirgen Therapeutics, Inc., a Baltimore-based biotechnology company focused on the discovery, development, and commercialization of therapies for genetic diseases and vaccines, received confirmation from the U.S. Food and Drug Administration (FDA) that its Investigational New Drug (IND) application for its lead candidate, EXG34217, was approved on May 23, 2020. EXG34217 is an autologous cell therapy for telomere biology disorders with bone marrow failure.

The FDA's approval allows Elixirgen Therapeutics to proceed with its planned Phase I/II, open label, single center clinical trial to assess the safety and tolerability of EXG34217 at Cincinnati Children's Hospital Medical Center (ClinicalTrials.gov Identifier: NCT04211714). This program's treatment paradigm uses Elixirgen Therapeutics' proprietary ZSCAN4 technology to extend the telomeres of the hematopoietic stem cells of the patients.

About Elixirgen Therapeutics, Inc.Elixirgen Therapeutics, Inc. is a Baltimore-based biotechnology company co-founded by Akihiro Ko and Minoru Ko, MD, PhD, which is focused on curing humanity's ailments through innovations in stem cell biology.The company's experienced team of researchers has a wide variety of specialties, enabling it to use both basic and translational research approaches to developing therapies for genetic diseases and vaccines. For more information visit https://ElixirgenTherapeutics.com

Forward-Looking StatementsThis press release may contain "forward-looking" statements, including statements regarding the effectiveness of EXG34217 to treat telomere biology disorders with bone marrow failure and statements relating to the planned clinical trials of EXG34217. Actual results may differ materially from those set forth in this press release due to the risks and uncertainties inherent in drug research and development. In light of these and other uncertainties, the forward-looking statements included in this press release should not be regarded as a representation by Elixirgen Therapeutics that its plans and objectives regarding EXG34217 will be achieved. Any forward-looking statements in this press release speak only as of the date of this press release, and Elixirgen Therapeutics undertakes no obligation to update or revise the statementsin the future, even if new information becomes available.

Contact:Media RelationsElixirgen Therapeutics, Inc.(443) 869-5420Media@ElixirgenTherapeutics.com

Follow this link:
FDA Approves Elixirgen Therapeutics IND Application for Therapy for Telomere Biology Disorders with Bone Marrow Failure - Herald-Mail Media